|
|
|
xi | |
| Acknowledgements |
|
xiii | |
|
|
|
1 | (24) |
|
|
|
|
|
1 | (1) |
|
1.2 Reverse genetics for different classes of genome |
|
|
2 | (3) |
|
|
|
5 | (6) |
|
1.4 Difficulties in establishing a reverse genetics system |
|
|
11 | (2) |
|
|
|
13 | (1) |
|
1.6 Are there any boundaries for conducting reverse genetics? |
|
|
13 | (12) |
|
|
|
15 | (10) |
|
Part I Positive sense RNA viruses |
|
|
25 | (88) |
|
2 Coronavirus reverse genetics |
|
|
27 | (37) |
|
|
|
|
|
|
|
|
|
|
|
|
|
27 | (1) |
|
2.2 Infectious bronchitis |
|
|
28 | (1) |
|
2.3 Coronavirus genome organisation |
|
|
29 | (1) |
|
2.4 The coronavirus replication cycle |
|
|
30 | (3) |
|
2.5 Development of reverse genetics system for coronaviruses including IBV |
|
|
33 | (4) |
|
2.6 Reverse genetics system for IBV |
|
|
37 | (3) |
|
2.7 Reverse genetics systems for the modification of coronavirus genomes |
|
|
40 | (9) |
|
2.8 Using coronavirus reverse genetics systems for gene delivery |
|
|
49 | (15) |
|
|
|
51 | (1) |
|
|
|
51 | (13) |
|
3 Reverse genetic tools to study hepatitis C virus |
|
|
64 | (27) |
|
|
|
3.1 Introduction: hepatitis C |
|
|
64 | (1) |
|
|
|
65 | (3) |
|
3.3 Construction of infectious clones for hepatitis C virus |
|
|
68 | (1) |
|
3.4 Study of HCV RNA replication in cell culture systems |
|
|
68 | (2) |
|
3.5 Use of HCV replicons to study viral replication |
|
|
70 | (1) |
|
3.6 Utility of replicons for drug screening |
|
|
71 | (1) |
|
3.7 Development of the infectious cell culture systems for HCV |
|
|
71 | (1) |
|
3.8 Construction of intergenotypic viral chimeras |
|
|
72 | (2) |
|
3.9 Non-JFH1 derived genomes |
|
|
74 | (1) |
|
3.10 Cell lines that support HCV replication |
|
|
74 | (1) |
|
3.11 Study of HCV in physiologically more relevant cell culture systems |
|
|
75 | (1) |
|
3.12 Animal models for HCV infection |
|
|
76 | (1) |
|
3.13 Reverse genetics of clinically relevant HCV genotypes in vivo |
|
|
77 | (1) |
|
|
|
78 | (13) |
|
|
|
78 | (1) |
|
|
|
78 | (13) |
|
4 Calicivirus reverse genetics |
|
|
91 | (22) |
|
|
|
|
|
91 | (2) |
|
|
|
93 | (4) |
|
|
|
97 | (6) |
|
4.4 Porcine enteric calicivirus |
|
|
103 | (1) |
|
4.5 Rabbit haemorrhagic disease virus |
|
|
104 | (1) |
|
|
|
104 | (2) |
|
|
|
106 | (7) |
|
|
|
107 | (1) |
|
|
|
107 | (6) |
|
Part II Negative sense RNA viruses |
|
|
113 | (138) |
|
5 Reverse genetics of rhabdoviruses |
|
|
115 | (35) |
|
|
|
|
|
5.1 Introduction: the Rhabdoviridae family |
|
|
115 | (6) |
|
5.2 Rhabdovirus reverse genetics |
|
|
121 | (11) |
|
5.3 Applications and examples |
|
|
132 | (5) |
|
|
|
137 | (13) |
|
|
|
137 | (1) |
|
|
|
137 | (13) |
|
6 Modification of measles virus and application to pathogenesis studies |
|
|
150 | (50) |
|
|
|
|
|
|
|
150 | (1) |
|
|
|
150 | (1) |
|
6.3 Measles: the infectious agent |
|
|
151 | (3) |
|
6.4 RNA synthesis: a tail of two processes |
|
|
154 | (1) |
|
6.5 Transcription: starting, stopping, dropping off or starting again |
|
|
154 | (1) |
|
6.6 From transcription to replication: the elusive switch |
|
|
155 | (2) |
|
6.7 Getting in and getting out |
|
|
157 | (1) |
|
6.8 Measles virus: reverse genetics |
|
|
158 | (23) |
|
|
|
181 | (19) |
|
|
|
182 | (1) |
|
|
|
182 | (18) |
|
7 Bunyavirus reverse genetics and applications to studying interactions with host cells |
|
|
200 | (24) |
|
|
|
7.1 Introduction: the family Bunyaviridae |
|
|
200 | (1) |
|
7.2 Bunyavirus replication |
|
|
201 | (2) |
|
7.3 History of bunyavirus reverse genetics |
|
|
203 | (2) |
|
7.4 Minigenome systems for bunyaviruses |
|
|
205 | (2) |
|
7.5 Virus-like particle production |
|
|
207 | (1) |
|
7.6 Rescue systems for bunyaviruses |
|
|
208 | (1) |
|
7.7 Application of reverse genetics to study bunyavirus replication |
|
|
208 | (7) |
|
|
|
215 | (9) |
|
|
|
216 | (8) |
|
8 Using reverse genetics to improve influenza vaccines |
|
|
224 | (27) |
|
|
|
|
|
|
|
|
|
224 | (3) |
|
|
|
227 | (2) |
|
8.3 The use of reverse genetics to generate recombinant influenza A, B and C viruses |
|
|
229 | (3) |
|
8.4 Using reverse genetics technology for generation of pandemic virus vaccine |
|
|
232 | (3) |
|
8.5 Other strategies for generating live attenuated vaccines based on viruses engineered by reverse genetics |
|
|
235 | (3) |
|
8.6 Strategies to improve the safety or yield of influenza vaccines |
|
|
238 | (1) |
|
8.7 Improvements to the PR8 high growth strain |
|
|
239 | (1) |
|
8.8 Improving the immunogenicity by engineering recombinant viruses that express cytokine genes |
|
|
240 | (1) |
|
8.9 Novel species-specific attenuation that takes advantage of microRNAs |
|
|
240 | (1) |
|
|
|
241 | (10) |
|
|
|
241 | (10) |
|
Part III Double-stranded RNA viruses |
|
|
251 | (68) |
|
9 Bluetongue virus reverse genetics |
|
|
253 | (36) |
|
|
|
9.1 Introduction to Bluetongue virus |
|
|
253 | (1) |
|
9.2 Bluetongue virus replication |
|
|
254 | (6) |
|
|
|
260 | (11) |
|
9.4 Uses of reverse genetics in orbivirus research |
|
|
271 | (7) |
|
|
|
278 | (11) |
|
|
|
281 | (8) |
|
10 Genetic modification in mammalian orthoreoviruses |
|
|
289 | (30) |
|
|
|
|
|
Diana J.M. van den Wollenberg |
|
|
Peter A.E. Sillevis Smitt |
|
|
|
|
|
|
289 | (7) |
|
10.2 Forward-genetics in orthoreoviruses |
|
|
296 | (1) |
|
10.3 Reovirus/cell interactions |
|
|
297 | (4) |
|
10.4 Reverse-genetics in orthoreoviruses |
|
|
301 | (5) |
|
10.5 Reovirus as an oncolytic agent |
|
|
306 | (2) |
|
|
|
308 | (11) |
|
|
|
309 | (10) |
|
Part IV Recent and future developments |
|
|
319 | (56) |
|
11 Reverse genetics and quasispecies |
|
|
321 | (29) |
|
|
|
|
|
11.1 Definition of quasispecies and evidence |
|
|
321 | (7) |
|
11.2 Reverse genetics and RNA virus population heterogeneity: consensus is always a compromise |
|
|
328 | (5) |
|
11.3 Examples of the use of the theory to disable or manipulate the quasispecies under controlled environments |
|
|
333 | (6) |
|
11.4 Future prospects of virus population genetics and reverse genetics |
|
|
339 | (2) |
|
|
|
341 | (9) |
|
|
|
342 | (8) |
|
12 Summary and perspectives |
|
|
350 | (25) |
|
|
|
|
|
350 | (1) |
|
12.2 Analysis of the role of specific non-coding sequence motifs involved in replication, transcription, polyadenylation and packaging |
|
|
351 | (1) |
|
12.3 Analysis of the roles of viral proteins |
|
|
352 | (1) |
|
12.4 Analysis of virus-host interactions at a global level |
|
|
353 | (1) |
|
12.5 Understanding the basis of pathogenicity |
|
|
354 | (1) |
|
12.6 Real-time virus imaging in vitro and in vivo |
|
|
355 | (1) |
|
12.7 Structure-function analysis of viruses and viral domains |
|
|
356 | (1) |
|
|
|
357 | (2) |
|
|
|
359 | (2) |
|
12.10 Gene delivery and knock-out in plant cells including virus-induced gene silencing (VIGS) |
|
|
361 | (1) |
|
12.11 Gene delivery in arthropod and mammalian cells |
|
|
362 | (1) |
|
12.12 Development of oncolytic virus and adaptation to this purpose |
|
|
363 | (1) |
|
12.13 Personal highlights and future directions |
|
|
364 | (11) |
|
|
|
366 | (9) |
| Index |
|
375 | |